Brokerages Set SI-BONE, Inc. (NASDAQ:SIBN) Target Price at $23.00

SI-BONE, Inc. (NASDAQ:SIBN - Get Free Report) has been given an average rating of "Buy" by the six ratings firms that are currently covering the stock, Marketbeat reports. Six analysts have rated the stock with a buy recommendation. The average 12-month price target among brokerages that have covered the stock in the last year is $23.00.

A number of analysts have recently commented on the stock. Needham & Company LLC reissued a "buy" rating and issued a $19.00 price objective on shares of SI-BONE in a research report on Wednesday, November 20th. Truist Financial boosted their price objective on shares of SI-BONE from $16.00 to $18.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th.

Insiders Place Their Bets

In other news, CFO Anshul Maheshwari sold 2,439 shares of the stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $12.68, for a total value of $30,926.52. Following the transaction, the chief financial officer now directly owns 194,623 shares of the company's stock, valued at $2,467,819.64. This represents a 1.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Laura Francis sold 10,048 shares of the stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $12.58, for a total transaction of $126,403.84. Following the completion of the transaction, the chief executive officer now directly owns 482,875 shares in the company, valued at $6,074,567.50. The trade was a 2.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 27,348 shares of company stock valued at $356,349. 3.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On SI-BONE

Several large investors have recently modified their holdings of the stock. Rhumbline Advisers grew its stake in shares of SI-BONE by 1.5% in the second quarter. Rhumbline Advisers now owns 59,419 shares of the company's stock valued at $768,000 after acquiring an additional 852 shares in the last quarter. Arizona State Retirement System grew its stake in shares of SI-BONE by 9.0% in the second quarter. Arizona State Retirement System now owns 10,921 shares of the company's stock valued at $141,000 after acquiring an additional 903 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of SI-BONE by 7.5% in the second quarter. The Manufacturers Life Insurance Company now owns 15,880 shares of the company's stock valued at $205,000 after acquiring an additional 1,105 shares in the last quarter. FMR LLC grew its stake in shares of SI-BONE by 103.6% in the third quarter. FMR LLC now owns 2,354 shares of the company's stock valued at $33,000 after acquiring an additional 1,198 shares in the last quarter. Finally, Franklin Resources Inc. grew its stake in shares of SI-BONE by 9.4% in the third quarter. Franklin Resources Inc. now owns 20,220 shares of the company's stock valued at $265,000 after acquiring an additional 1,745 shares in the last quarter. 98.11% of the stock is owned by institutional investors.

SI-BONE Stock Down 4.7 %

Shares of SI-BONE stock traded down $0.68 on Friday, hitting $13.72. The company had a trading volume of 412,087 shares, compared to its average volume of 281,598. The firm has a market capitalization of $575.39 million, a P/E ratio of -14.91 and a beta of 1.16. SI-BONE has a twelve month low of $11.70 and a twelve month high of $21.64. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22. The stock has a 50-day moving average of $13.68 and a 200-day moving average of $14.21.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.